Skip to content

Neuropace, Inc. NPCE Earnings yield

Earnings yield at other companies

Medtronic logo
MedtronicMDT
4.6%+0.3pp
LivaNova logo
LivaNovaLIVN
-7.6%-8.4pp
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-10.8%+25.3pp
Inspire Medical Systems logo
Inspire Medical SystemsINSP
8.8%+7.4pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-13%-3.9pp
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
-24.8%-26.2pp

Other financials

Income statement

See full
Revenue$22.1M-2.0%
Gross profit$18.0M+4.1%
Operating income-$5.6M-8.2%
Net income-$6.7M-1.5%
EPS (diluted)-$0.20+4.8%

Balance sheet

See full
Cash & equivalents$15.6M-42.4%
Total debt$70.5M-3.7%
Total equity$14.5M-40.4%
Total assets$98.9M-10.3%

Cash flow

See full
Operating cash flow-$5.9M+21.1%
CapEx$117.0K+216%
Free cash flow-$6.0M+20.0%

Valuation

See full
Market cap$557.77M+63.4%
Enterprise value$612.6M+58.1%
P/S5.6×+1.6×

Profitability

See full
Gross margin78.3%+3.5pp
Operating margin-16.8%-3.5pp
Net margin-21.7%-4.5pp
FCF margin-10.3%-3.5pp

Returns & leverage

See full
Return on equity-111.4%-13.1pp
Debt / equity4.9×+1.9×
Current ratio5.4×-1.2×

Where this comes from

Calculated from Neuropace, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuropace, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuropace, Inc.'s earnings yield?
Neuropace, Inc. (NPCE) reported earnings yield of -4.9% in Q1 2026.
How has Neuropace, Inc.'s earnings yield changed year-over-year?
Neuropace, Inc.'s earnings yield increased by 21.4% year-over-year, from -6.2% to -4.9%.
What is the long-term trend for Neuropace, Inc.'s earnings yield?
Over 4 years (2021 to 2025), Neuropace, Inc.'s earnings yield has grown at a -27.0% compound annual growth rate (CAGR), from -14.7% to -4.2%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.